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1086-139 Comparison Between Successful and Unsuccessful 
Mitral Valve Repair of Ischemic Mitral Regurgitation: An 
Echocardiographic Follow-Up Study
Maiko Shiota, Jian Xin Qin, Patrick M. McCarthy, A. Marc Gillinov, John-Han Shin, 
Timothy Williams, Delos M. Cosgrove, James D. Thomas, Takahiro Shiota, Cleveland 
Clinic Foundation, Cleveland, OH
Ischemic mitral regurgitation (IMR) is commonly treated by ring annuloplasty, but it is
unclear what factors contribute to the success of annular reduction surgery. This study
aimed to investigate predictive echo factors for the success of mitral valve (MV) repair.
Methods: 437 patients underwent MV repair for IMR at Cleveland Clinic Foundation
between April 1990 and November 2002. 76 patients were excluded from this study due
to insufficient or inconsistent echo reports or clinical information. Pre-operative echo data
in the remaining 361 patients were analyzed, including ejection fraction (EF), left atrial
diameter (LAD), left ventricular end-diastolic diameter (LVDD) and end-systolic diameter
(LVSD). Severity of mitral regurgitation (MR) was graded on a scale of 0 to 4.
Results (Table): 298 patients (83%) had satisfactory outcomes with <2+ MR, while 63
(17%) had recurrent significant MR (>2+) during follow-up. There was no significant dif-
ference in age, sex, EF and follow up period between the 2 groups. The success group
was found to have a smaller LAD, LVDD, and LVSD pre-operatively than the recurrent MR
group. The most striking difference between the two groups was the severity of MR
before repair. 
Conclusion: LAD, LVDD, LVSD and especially MR severity in preoperative 2D echo were
larger or worse in the recurrent MR group as compared to the success one. Accordingly,
MV repair should be carefully selected in IMR patients with larger left atrium/left ventricle
and more severe MR.
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1107-135 Neoangiogenesis via Vascular Endothelial Growth 
Factor Expression Is Associated With an Osteoblast-
like Bone Formation in Calcified Rheumatic Heart 
Valves
Thomas B. Nealis, Stuart Stock, Khuram H. Siddiqi, Thenappan Thenappan, Thomas C. 
Sebo, Stephen W. Carmichael, James Frederiksen, Malayannan Subramanium, William 
D. Edwards, Thomas C. Spelsberg, Robert O. Bonow, Nalini M. Rajamannan, 
Northwestern University, Chicago, IL, Mayo Clinic, Rochester, MN
Intro: Rheumatic fever is the most common cause of valvular heart disease in developing
countries. Despite its high prevalence, the inflammatory-immune and fibrocalcific mecha-
nisms leading to progressive valvular dysfunction are not well characterized. We hypoth-
esized that calcification is associated with osteoblastic bone formation and angiogenesis.
Methods: To test this hypothesis we examined human rheumatic valves (RV) replaced at
surgery (n=23) and normal human valves (nl) (n=20). Micro computed tomography was
used to assess mineralization fronts to reconstruct the 2 dimensional and 3 dimensional
extent of mineralization. Hematoxylin and eosin, Masson trichrome stains were per-
formed. Immunohistochemistry was used to localize osteopontin protein, alpha actin,
CD34, Vascular Endothelial Growth Factor (VEGF), von willebrand factor (VWF), and
CD68 stains (human macrophage). Quantification of PCNA was performed by computer
analysis (Quantification of Proliferation Index Baccus, Inc, Lombard, IL). Results: H and
E, and Masson Trichrome stains confirmed the presence of mineralization in areas of
intense calcification of the calcified rheumatic heart valves as compared to normal
valves. Immunohistochemistry localized osteopontin to smooth muscle cells within the
microvessels within the valves. MicroCT demonstrated calcification with complex forma-
tions developing within the mineralized tissues. Immunohistochemistry markers including
VEGF and CD34 for angiogenesis were positive in areas of inflammation (CD68). In cells
staining for alpha-actin, PCNA index was positive in 5 of 22 cardiac valves in the alpha
actin staining cells (1.26+/-0.32 (nl) versus 37.64 (RV)). The amount of new vessels
present were positive in 19 of 22 valves (0 (nl) versus 21.55+/-22.08(RV)). These mark-
ers were present minimally in the normal valves. Conclusions: These findings strongly
suggest that rheumatic valve calcification results from ongoing osteoblast bone formation
and neoangiogenesis. Neither of those cellular processes are passive or random; both
are active and regulated by multiple inflammatory mediators which are important in bone
formation.
1107-136 Progression of Aortic Valve Calcification Measured by 
Electron Beam Computed Tomography: A Population-
Based Study
David Messika-Zeitoun, Lawrence F. Bielak, Patricia A. Peyser, Patrick F. Sheedy, II, 
Jerome Breen, Marie-Christine Aubry, Maurice Enriquez-Sarano, Mayo Clinic, Rochester, 
MN, University of Michigan, Ann Arbor, MI
Background: Calcification of the aortic valve has been recently linked to poor outcome.
However, prevalence, progression and association to cardiovascular risk factors and sub-
clinical atherosclerosis are unknown
Methods: Between 1996 and 1999, 262 research participants >60 years (68±5 years,
43% male) enrolled in a prospective population-based study underwent Electron Beam
Computed Tomography (ECBT) for assessment of aortic valve (AVC) and coronary artery
(CAC) calcifications
Results: Prevalence: Prevalence of AVC was 30% and increased with age (<65 years:
15%; 65-70 years: 35% and >70 years: 42%; p<0.01) Association to cardiovascular risk
factors and CAC: History of diabetes and hypertension, serum glucose and body mass
index were significantly associated with AVC (all p<0.05). Patients with AVC had higher
CAC (441±802 vs. 265±566, p<0.01) independent of age Progression: After a mean fol-
low-up of 3.8±0.9 years, AVC increased (baseline: 54±173, follow-up: 94±271, p<0.01)
and more so in patients with than without baseline AVC (+37±53 vs. +1±4 /year, p<0.01).
Overall, independent predictors of AVC progression were baseline AVC (p<0.01) and
LDL-C (p<0.01). Compared to the 173 AVC-free participants (baseline and follow-up),
total and LDL-C and CAC progression (adjusted for baseline score) were higher in the 19
with AVC-acquisition at follow-up (respectively 235±39 vs. 209±33 mg/dL; 141±31 vs.
121±27 mg/dL; +78±87 vs. +28±47 /year, all p<0.01) but not in the 70 with established
AVC at baseline (respectively 205±35; 120±31; +53±58; all p>0.40). LDL-C was the only
independent determinant of acquisition of AVC and baseline AVC of progression of AVC
in the AVC established group
Conclusion: In the population, AVC 1) is frequent and increases with age, 2) is associ-
ated with atherosclerotic risk factors, 3) is a marker of more severe coronary artery dis-
ease a potential mechanism for poor outcome 4) appears de novo in a context of
progressive atherosclerosis 5) whereas established AVC progresses independently of
atherosclerotic risk factors and faster with increasing AVC loads. These data underscore
the importance of AVC measurement by EBCT and of evaluating strategies to slow the
disease progression
1107-137 Influence of C-Reactive Protein on Matrix Remodeling in 
Calcific Aortic Stenosis
Jens J. Kaden, Carl-Erik Dempfle, Hanh-Thai Tran, Siegfried Lang, Rainer Grobholz, 
Siegfried Hagl, Martina Brueckmann, Karl K. Haase, Martin Borggrefe, University 
Hospital Mannheim, Mannheim, Germany, University Hospital Heidelberg, Heidelberg, 
Germany
Background: Calcific aortic stenosis (AS) is based on an inflammatory process leading
to marked remodeling of the extracellular matrix. We have shown that matrix metallopro-
teinase (MMP)-1 contributes to this process. Recent studies showed that serum levels of
the inflammatory mediator C-reactive protein (CRP) are elevated in patients with calcific
AS, however, its the role during the pathogenesis of calcific aortic stenosis is unknown.
Methods: Human tricuspid aortic valves with calcific AS (n=11) were obtained at valve
replacement, sclerotic valves without stenosis (n=5) and normal valves (n=4) at autopsy.
CRP immunostaining was performed using monoclonal antibodies, and staining intensi-
ties were assessed by semiquantitative scoring. Human aortic valve myofibroblasts were
cultured with and without addition of CRP. MMP-1 expression was assessed by Western
blotting.
Results: No staining for CRP was detectable in normal valves. Sclerotic valves showed
moderate staining, stenotic valves intense staining (p<0.05 by Kruskal-Wallis test). Stim-
ulation of human aortic valve myofibroblasts with CRP lead to a time-dependent increase
in MMP-1 as compared to unstimulated controls.
Conclusion: CRP staining is absent in normal valves, present in sclerotic valves and
strong in stenotic valves. Stimulation of cultured human aortic valve myofibroblasts with
CRP leads to increased expression of MMP-1. These results suggest a pathogenetic
influence of CRP on tissue remodeling during calcific AS, further supporting the concept
of calcific AS as an inflammatory disorder.
1107-138 Statin Therapy Does Not Affect Bioprosthetic Valve 
Degeneration
Raphael Rosenhek, Florian Rader, Maria Heger, Harald Gabriel, Thomas Binder, Gerald 
Maurer, Helmut Baumgartner, University of Vienna, Vienna, Austria
Background: Several recent studies have suggested that statins reduce the hemody-
namic progression of calcific aortic stenosis. Similarly, a slower rate of bioprosthetic valve
degeneration has recently been reported for statin-treated patients. However, the differ-
ences in underlying pathophysiolgical mechanisms of these two disorders question such
positive statin effects. Thus, further retrospective analyses are required before prospec-
tive randomized trials can be justified.
Methods: 202 pts (71±11 years, 118 female) with bioprosthetic aortic valves, normal left
ventricular function and no other significant valvular lesion who were examined between
2000 and 2002 and who had two echocardiograms separated by at least 6 months were
studied (mean interval 28±17 months). Of these, 84 pts (42%) were on statin therapy.
The change in peak transprosthetic velocity (TP-Vel) during follow-up was assessed.
No Recurrent MR Recurrent MR P-value
Data Availability (N) 298 63
Days of Follow-up 262±546 190±384 NS
Age (years) 66±9 67±8 NS
Male/Female 193/105 39/24 NS
EF (%) 33±11 32±10 NS
LAD (cm) 4.56±0.8 4.89±0.6 0.01
LVDD (cm) 5.77±0.86 6.06±0.71 0.04
LVSD (cm) 4.09±1.03 4.85±0.74 0.03
Pre-Op MR (0~4+) 2.67±0.84 3.15±0.86 <0.0001
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Results: The average annualized increase of TP-Vel for the entire study group was small
(0.04±0.28m/s/yr) and did not significantly differ between patients receiving statins
(0.02±0.29 m/s/yr) and those who did not (0.05±0.28 m/s/yr; p=0.48). However, there
was a wide variability of the progression rate. 32 pts had a rapid increase of TP-Vel
defined as >0.25 m/s/yr. Such a rapid progression was observed in 17% (14 of 84) of pts
treated with statins and 15% (18 of 118) of pts who were not (p=0.79). From these find-
ings it appears unlikely that statins delay hemodynamic deterioration of bioprosthetic
valves.
Coronary artery disease, hypertension, age, gender, hypercholesteremia and prosthetic
valve type were not related to the progression rate of TP-Vel. However there was a trend
towards more rapid increase of TP-Vel in diabetic pts (0.13±0.37 vs. 0.02±0.26 m/s/yr,
p=0.06). In particular, rapid hemodynamic deterioration (TP-Vel >0.25 m/s/yr) was
observed in 29% (10 of 34) of the diabetic pts compared to 13% (22 of 168) of the non-
diabetic pts (p=0.03).
Conclusion: In contrast to calcific aortic stenosis, statins do not appear to affect biopros-
thetic valve degeneration. This further underscores the different mechanisms involved in
these two disorders.
1107-139 Calcium-Phosphorus Product Is Associated With 
Severity of Aortic Stenosis in Patients With Normal 
Renal Function
William R. Mills, Douglas Einstadter, Robert S. Finkelhor, Case Western Reserve 
University, MetroHealth Campus, Cleveland, OH
Background: Recent investigations have shown that acquired aortic stenosis (AS) may
result from production of bone matrix proteins by osteoblast-like cells which can mineral-
ize in the presence of phosphorus and other triggers. Elevated serum phosphorus and
calcium-phosphorus product (CaxP) have been associated with increased aortic valve
calcification in dialysis patients, but it is unknown whether such a relationship exists in
patients with normal renal function.
Methods: Between November 2001 and October 2002, 107 consecutive AS patients with
a serum creatinine <1.5 were identified. Aortic valve area (AVA) was calculated by the
echocardiographic continuity equation. Clinical and laboratory data obtained within 3
months of the index echo were determined by chart review.
Results: The study sample included 40 men and 67 women. Mean parameters were as
follows: creatinine 0.9±0.3 mg/dl, age 74±12 years, AVA 1.1± 0.35cm2, phosphorus
3.7±0.7mg/dl, CaxP 32.7±7.1, peak gradient 39.6+21.9mmHg, and mean gradient
23.5+12.9mmHg. Both serum phosphorus (R= -0.248, p=0.028) and CaxP (R= -0.303,
p=0.007) were inversely related to AVA. CaxP was positively correlated with peak
(R=0.227, p=0.044) and mean R=0.235, p=0.039) gradients. Further, in linear regression
analysis, a one mg/dl increase in serum phosphorus was associated with a 0.13 cm2
(95% CI of -0.2 to -0.01, p<0.03) decrease in the AVA, and a one unit increase in CaxP
was associated with a 0.02cm2 (-0.03 to -0.01, p<0.01) decrease in the AVA.
Conclusions: Higher levels of serum phosphorus and CaxP are associated with more
severe AS. These findings support the hypothesis that increased serum phosphorus and
CaxP may be important triggers leading to severe AS, even in patients with normal renal
function.
1107-140 Lack of Association Between Severity of Coronary 
Artery Disease and Aortic Valve Calcification 
Determined by Atomic Absorption Spectroscopy in 187 
Patients With Aortic Valve Replacement
Jan R. Ortlepp, Fabian Schmitz, Vera Mevissen, Stefan Weiß, Jürgen Huster, Richard 
Dronskowski, Rüdiger Autschbach, Georg Langebartels, Peter Hanrath, University of 
Technology Aachen, Aachen, Germany
Background: Coronary artery disease (CAD) and aortic stenosis share many similarities
and calcification of the aortic valve is closely linked to CAD. In a previous study we have
demonstrated the lack of association of risk factors and valve calcification and the impact
of genetic factors. In this analysis we evaluated the relationship between the degree of
valve calcification and the degree of angiographic determined CAD.
Methods: The amount of calcification (hexagonal hydroxyapatite) of 187 excised stenotic
aortic valves was determined using atomic absorption spectroscopy (mass%). CAD type
were defined prior to aortic valve replacement by coronary angiography as (I) angio-
graphically clear coronaries, (II) coronary sclerosis, and (III) stenotic (>50%) CAD. Sever-
ity of CAD was defined as the number of needed coronary artery bypass grafts (CABG)
per patient (none, 1, 2, 3, more than 3).
Results: 48 patients had clear coronaries, 43 had coronary sclerosis, 96 patients had
stenotic CAD. 95 patients underwent CABG (1 CABG: 37 patients; 2 CABG: 27 patients;
3: CABG 20 patients; more than 3 CABG: 11 patients). There was neither an association
between the type of CAD (23.4 ± 11.3 vs 25.5 ± 8.8 vs 23.0 ± 8.6; p=0.326) nor the num-
ber of CABG (24.2 ± 10.3 vs 23.9 ± 8.1 vs 21.1 ± 9.8 vs 23.2 ± 8.9 vs 25.2 ±6.4;
p=0.610) and the exact determined degree of hydroxyapatite in the valve.
Conclusion: At the time of surgery there was no association between the severity of aor-
tic valve calcification and the severity of CAD in patients with relevant aortic valve steno-
sis who underwent aortic valve replacement. While aortic sclerosis seems to be an
excellent marker for CAD, severity of CAD does not have a close link to the extend of
severe aortic valve calcification.
ORAL CONTRIBUTIONS
824FO Featured Oral Session...Percutaneous 
Approaches to Cardiac Valve Repair and 
Replacement
Monday, March 08, 2004, 4:00 p.m.-5:30 p.m.
Morial Convention Center, Room 243
4:15 p.m.
824-2 The In Vitro Functions of a Percutaneous Heart Valve in 
the Aortic Position
David Paniagua, Jose M. Cesar, Eduardo Induni, Carolyne Ortiz, Carlos Mejia, Richard 
T. Schoephoerster, R. David Fish, Endoluminal Technology Research, Miami Beach, FL, 
Florida Internatrional University, Miami, FL
Background
We developed a new folded pericardial valve with a low profile that allows percutaneous
implantation. We tested this valve in a validated left heart and systemic circulation simu-
lator (Vivitro Systems, Victoria Canada).
Methods 
Five 20 mm diameter percutaneous heart valves (PHV) were evaluated in the left heart
simulator in the aortic position. This system includes a processor controlled stepper
motor that drives a piston cylinder, forcing contraction and relaxation of the left ventricular
sac. The aortic valves are mounted in relative anatomical positions. The system is filled
with fluid containing 70% water and 30% glycerol to achieve the same density and vis-
cosity as blood. Sodium chloride at 0.9% is added to allow measuring of flow using an
electromagnetic probe. The PHV function was evaluated under physiological conditions:
cardiac output 5 liters/min, heart rate of 70/min and blood pressure of 180/80 and patho-
logical conditions of hypotension (70/40) and hypertension (320/250). Comparison with
the St Jude mechanical heart valve was done for backflow percentage. Echo-Doppler
studies of the PHV were performed with a 7.5 MHz transducer in the in-vitro testing
model.
Results
The PHV had no transvalvular gradient and no backflow (regurgitation) at physiological
conditions (graph) compared with a 14% leakage of the St Jude valve.
The opening gradient of the PHV was 5 mmHg. No evidence of prolapsing was seen dur-
ing extreme hypertension (320/250). The PHV opening and closing characteristics were
fully competent even in hypotensive (70/40) conditions. Two-dimensional images showed
complete apposition of the leaflets with appreciation of the “Mercedes Benz” sign. Pulse
Doppler studies of the PHV in vitro model were performed demonstrating no evidence of
regurgitation and physiological forward velocity.
Conclusion
Our PHV shows fully competent hemodynamic and Echo-Doppler performance in a vali-
dated left heart and systemic circulation simulator (Vivitro Systems). This new PHV
design has significantly less backflow than the St Jude mechanical aortic valve.
4:30 p.m.
824-3 Percutaneous Implantation of a New Prosthetic Heart 
Valve in the Descending Aorta in Sheep: Results at Six 
Weeks in a Model of Severe Aortic Insufficiency
Hélène Eltchaninoff, Danielle Nusimovici, Assaf Bash, Alain Cribier, Charles Nicolle 
Hospital, Rouen, France, Percutaneous Valve Technologies, Fort Lee, NJ
Background: Hufnagel in the 50s, showed that the implantation of a mechanical valve in
the descending aorta of patients with aortic insufficiency (AI) decreased the regurgitant
flow. In the sheep model, creation of a severe AI consistently leads to early death. The
goals of this study were to assess the efficacy on survival and the long-term performance
of a percutaneous heart valve (PHV), made of 3 equine pericardial leaflets mounted in a
balloon-expandable stent, implanted in the proximal descending aorta of the sheep after
creation of a severe AI. Efficacy of this PHV has been previously reported.
Methods: AI was created by an original technique using a 7F biotome to extract a small
fragment of aortic valve leaflet. Severe AI was defined by massive filling of the left ventri-
cle on supra-aortic angiogram with a fall in aortic diastolic pressure (DBP) > 20 mmHg.
Crimped over a 22 mm diameter balloon, the PHV was then introduced through a 24 F
sheath in the carotid artery, advanced over a stiff wire and delivered in the descending
aorta. PHV function was assessed on hemodynamics, angiography, 2D-and trans-esoph-
ageal echocardiography (TEE) and Doppler. TEE and Doppler were repeated at 6 weeks.
Results: 13 sheep (8.9 + 0.7 mths; 41 + 5 Kg) were studied. Severe AI and accurate
PHV delivery were obtained in all cases. Decrease in DPB was 28 + 11 mm Hg. Three
animals died acutely of biotomy related hemorrhagic complications. On echocardio-
graphy, post-PHV AI was grade 2 in 2, grade 3 in 7 and grade 4 in 1. PHV valve area was
1.97 + .06 cm2, with no leak in 8, mild and moderate leaks in 2. Post-PHV treatment was
aspirin (150 mg/d) and enoxaparin (40 mg/d). All 10 sheep were alive at 6 weeks. TEE
was obtained in 9/10 (poor echogenicity in 1): one PHV had migrated and all other were
functioning well. PHV valve area was 1.96 + .05 cm2 with no leak in one, mild leak in 4,
moderate leak in 4. AR on the native valve was unchanged in 3 sheep, and decreased by
1 grade in others.
Conclusions: PHV implantation in the descending aorta prevents animal death despite
severe AI and shows good immediate and 6-week results. Six-month follow-up is ongo-
ing. In the future, this technique might offer a new therapeutic option to patients with non-
operable AI.
